Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Cancer Biology;  Cytotoxic Therapy;  Tumour Immunology;  Cancer Registries;  Targeted Therapy;  Molecular Oncology;  Cancer Care Equity Principles and Health Economics;  Statistics;  Immunotherapy

Tumour Site

Presenters

Sebastian Albers

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

S. Albers1, J.C. Michaeli2, C.T. Michaeli3, D.T. Michaeli4

Author affiliations

  • 1 Klinik Und Poliklinik Für Unfallchirurgie, Klinikum rechts der Isar, Technische Universität München, 80333 - München/DE
  • 2 Department Of Gynecology And Obstetrics, Breast Center and CCC Munich, BZKF, Universitz Hospital Munich, LMU Munich, 81377 - Munich/DE
  • 3 Abteilung Für Personalisierte Onkologie Mit Schwerpunkt Lungenkarzinom, UMM - Universitaetsklinikum Mannheim, 68167 - Mannheim/DE
  • 4 Department Of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, 69120 - Heidelberg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 674P

Background

Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination. This study identifies and quantifies factors associated with patient accrual in trials leading to the US Food and Drug Administration (FDA) approval of new cancer drugs.

Methods

All cancer drugs with FDA approval were identified in the Drugs@FDA database (2000-2022). Data on drug indication’s background-, treatment-, disease-, and trial-related factors were collected from FDA labels, clinicaltrials.gov, and the Global Burden of Disease study. The association between patient accrual and collected variables was assessed in Poisson regression models reporting adjusted rate ratios (aRR) for randomized and single-arm trials.

Results

We identified 170 drugs with approval in 455 cancer indications based on 292 randomized and 163 single-arm trials. Among randomized trials, accrual rates were 0.30-times (p<0.001), 0.73-times (p<0.001), and 0.88-times (p=0.361) lower for ultra-rare, rare, and common than non-orphan indications. Accrual was positively associated with disease burden (aRR: 1.0003 per DALY, p<0.001), trial sites (aRR: 1.001 per site, p<0.001), participating countries (aRR: 1.02 per country, p<0.001), and phase 3 vs. 1/2 trials (aRR: 1.64, p=0.037). Enrollment was negatively associated with advanced-line vs. first-line treatments (aRR: 0.81, p=0.010) and monotherapy vs. combination treatments (aRR: 0.80, p=0.007). Accrual was 0.80-times lower (p=0.209) in government-sponsored vs. industry-sponsored trials. Results were consistent for single-arm trials.

Conclusions

Disease incidence and burden alongside the number of study sites and participating countries were significantly associated with patient accrual. For rare disease trials, greater financial incentives could expedite patient enrollment. Novel trial design features, including skewed randomization, crossover, or open-label masking, did not entice patient enrollment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.